{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T17:05:25Z","timestamp":1779469525765,"version":"3.53.1"},"reference-count":115,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Liposarcoma represents a heterogeneous group of mesenchymal malignancies with distinct molecular profiles and clinical behaviors. While localized disease is managed with surgical resection, advanced or metastatic liposarcoma poses a significant therapeutic challenge due to limited response to traditional cytotoxic chemotherapy. This review summarizes current evidence-based systemic therapies and highlights recent advances in subtype-driven treatment strategies. Methods: We review key clinical trials supporting the use of anthracycline regimens, trabectedin, eribulin, and nuclear export inhibition with selinexor, as well as emerging targeted approaches directed at MDM2 and CDK4 amplification. In addition, we discuss the evolving role of immunotherapy, including checkpoint inhibitors and engineered T-cell receptor therapies targeting cancer\u2013testis antigens. Results: Integrating molecular biology with therapeutic development, we emphasize the importance of histologic and genomic classification in guiding treatment selection and clinical trial design. Conclusion: Continued progress in biomarker-driven strategies and rational combination therapies is expected to further refine personalized treatment approaches and improve outcomes for patients with advanced liposarcoma.<\/jats:p>","DOI":"10.3390\/cancers18111694","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T16:06:08Z","timestamp":1779465968000},"page":"1694","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Evolving Landscape of Systemic Therapy for Liposarcoma"],"prefix":"10.3390","volume":"18","author":[{"given":"Hee Kyung","family":"Kim","sequence":"first","affiliation":[{"name":"Chao Family Comprehensive Cancer Center, University of California, Orange, CA 92868, USA"},{"name":"Division of Hematology\/Oncology, Department of Medicine, University of California, Orange, CA 92868, USA"},{"name":"Department of Internal Medicine, Chungbuk National University Hospital, Cheongju 28644, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshat","family":"Sarkari","sequence":"additional","affiliation":[{"name":"Chao Family Comprehensive Cancer Center, University of California, Orange, CA 92868, USA"},{"name":"Division of Hematology\/Oncology, Department of Medicine, University of California, Orange, CA 92868, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0889-5841","authenticated-orcid":false,"given":"Warren A.","family":"Chow","sequence":"additional","affiliation":[{"name":"Chao Family Comprehensive Cancer Center, University of California, Orange, CA 92868, USA"},{"name":"Division of Hematology\/Oncology, Department of Medicine, University of California, Orange, CA 92868, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"De Pinieux, G., Karanian, M., Le Loarer, F., Le Guellec, S., Chabaud, S., Terrier, P., Bouvier, C., Batistella, M., Neuville, A., and Robin, Y.M. (2021). Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0246958"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Resag, A., Toffanin, G., Bene\u0161ov\u00e1, I., M\u00fcller, L., Potkrajcic, V., Ozaniak, A., Lischke, R., Bartunkova, J., Rosato, A., and J\u00f6hrens, K. (2022). The immune contexture of liposarcoma and its clinical implications. Cancers, 14.","DOI":"10.3390\/cancers14194578"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"102668","DOI":"10.1016\/j.ctrv.2023.102668","article-title":"MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action","volume":"122","author":"Somaiah","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2214\/ajr.164.1.7998525","article-title":"Malignant soft-tissue tumors in a large referral population: Distribution of diagnoses by age, sex, and location","volume":"164","author":"Kransdorf","year":"1995","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.soc.2016.05.007","article-title":"Liposarcoma: Multimodality Management and Future Targeted Therapies","volume":"25","author":"Crago","year":"2016","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/01.sla.0000234795.98607.00","article-title":"Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk","volume":"244","author":"Dalal","year":"2006","journal-title":"Ann. Surg."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"416\u2013421; discussion 421\u2013412","DOI":"10.1097\/SLA.0000000000000869","article-title":"Lessons learned from the study of 10,000 patients with soft tissue sarcoma","volume":"260","author":"Brennan","year":"2014","journal-title":"Ann. Surg."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"70","DOI":"10.32074\/1591-951X-213","article-title":"The 2020 WHO Classification of Soft Tissue Tumours: News and perspectives","volume":"113","author":"Sbaraglia","year":"2021","journal-title":"Pathologica"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/annonc\/mdr323","article-title":"Frontline extended surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas","volume":"23","author":"Gronchi","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1200\/JCO.2017.74.9598","article-title":"Clinical and Molecular Spectrum of Liposarcoma","volume":"36","author":"Lee","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_11","unstructured":"National Comprehensive Cancer Network (2026, February 07). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Soft Tissue Sarcoma. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/sarcoma.pdf."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1177\/1758834017712963","article-title":"Treatment of advanced, metastatic soft tissue sarcoma: Latest evidence and clinical considerations","volume":"9","author":"In","year":"2017","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","article-title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: A randomised controlled phase 3 trial","volume":"15","author":"Judson","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1080\/0284186X.2017.1315173","article-title":"Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: A subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study","volume":"56","author":"Young","year":"2017","journal-title":"Acta Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1093\/annonc\/mdr485","article-title":"Advanced well-differentiated\/dedifferentiated liposarcomas: Role of chemotherapy and survival","volume":"23","author":"Italiano","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1016\/j.ejca.2005.07.023","article-title":"Differential sensitivity of liposarcoma subtypes to chemotherapy","volume":"41","author":"Jones","year":"2005","journal-title":"Eur. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"96","DOI":"10.21037\/tgh.2018.11.01","article-title":"Histology driven systemic therapy of liposarcoma-ready for prime time?","volume":"3","author":"Grethlein","year":"2018","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"11836","DOI":"10.1038\/s41598-017-12132-w","article-title":"Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: Defining the benefit and challenges of the standard","volume":"7","author":"Livingston","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1200\/JCO.2015.62.4734","article-title":"Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial","volume":"34","author":"Demetri","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S1470-2045(07)70175-4","article-title":"Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: A retrospective study","volume":"8","author":"Grosso","year":"2007","journal-title":"Lancet Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1158\/1535-7163.MCT-10-0263","article-title":"A review of trabectedin (ET-743): A unique mechanism of action","volume":"9","author":"Galmarini","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1634\/theoncologist.2016-0064","article-title":"Efficacy of Trabectedin in Patients with Advanced Translocation-Related Sarcomas: Pooled Analysis of Two Phase II Studies","volume":"22","author":"Takahashi","year":"2017","journal-title":"Oncologist"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.2353\/ajpath.2006.050872","article-title":"The myxoid\/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells","volume":"168","author":"Engstrom","year":"2006","journal-title":"Am. J. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1186\/s13046-024-03228-z","article-title":"Mechanism of efficacy of trabectedin against myxoid liposarcoma entails detachment of the FUS-DDIT3 transcription factor from its DNA binding sites","volume":"43","author":"Craparotta","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","article-title":"Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: A randomised, open-label, multicentre, phase 3 trial","volume":"387","author":"Schoffski","year":"2016","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1200\/JCO.2016.71.6605","article-title":"Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine","volume":"35","author":"Demetri","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"Blay","year":"2012","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2008.21.3223","article-title":"Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: A phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043)","volume":"27","author":"Sleijfer","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"483154","DOI":"10.1155\/2011\/483154","article-title":"Liposarcoma: Molecular genetics and therapeutics","volume":"2011","author":"Conyers","year":"2011","journal-title":"Sarcoma"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.molcel.2006.01.020","article-title":"p53 ubiquitination: Mdm2 and beyond","volume":"21","author":"Brooks","year":"2006","journal-title":"Mol. Cell"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Chinnam, M., Xu, C., Lama, R., Zhang, X., Cedeno, C.D., Wang, Y., Stablewski, A.B., Goodrich, D.W., and Wang, X. (2022). MDM2 E3 ligase activity is essential for p53 regulation and cell cycle integrity. PLoS Genet., 18.","DOI":"10.1371\/journal.pgen.1010293"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.molcel.2019.03.020","article-title":"Cyclin D-Cdk4,6 Drives Cell-Cycle Progression via the Retinoblastoma Protein\u2019s C-Terminal Helix","volume":"74","author":"Topacio","year":"2019","journal-title":"Mol. Cell"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Dong, P., Zhang, C., Parker, B.T., You, L., and Mathey-Prevot, B. (2018). Cyclin D\/CDK4\/6 activity controls G1 length in mammalian cells. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0185637"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Cassinelli, G., Pasquali, S., and Lanzi, C. (2022). Beyond targeting amplified MDM2 and CDK4 in well differentiated and dedifferentiated liposarcomas: From promise and clinical applications towards identification of progression drivers. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.965261"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1158\/1078-0432.CCR-08-3185","article-title":"Clinical and Biological Significance of CDK4 Amplification in Well-Differentiated and Dedifferentiated Liposarcomas","volume":"15","author":"Italiano","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S1470-2045(12)70474-6","article-title":"Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: An exploratory proof-of-mechanism study","volume":"13","author":"Blay","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"S1331","DOI":"10.1016\/j.annonc.2023.10.091","article-title":"LBA89 Efficacy and safety findings from MANTRA: A global, randomized, multicenter, phase III study of the MDM2 inhibitor milademetan vs trabectedin in patients with dedifferentiated liposarcomas","volume":"34","author":"Jones","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"117204","DOI":"10.1016\/j.biopha.2024.117204","article-title":"Molecular characteristics and systemic treatment options of liposarcoma: A systematic review","volume":"178","author":"Zhou","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"ref_39","unstructured":"Gounder, M. (2023). Milademetan versus Trabectedin in Patients with Advanced Dedifferentiated Liposarcoma (MANTRA): A Randomized, Open-Label, Phase 3 trial.ESMO Congress 2023, European Society for Medical Oncology (ESMO)."},{"key":"ref_40","first-page":"S48","article-title":"A phase Ia\/Ib study of the MDM2\u2013p53 antagonist brigimadlin (BI 907828): Safety and efficacy in patients with dedifferentiated liposarcoma","volume":"35","author":"Duffaud","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2217\/fon-2022-1291","article-title":"Brightline-1: Phase II\/III trial of the MDM2-p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS","volume":"19","author":"Lahmar","year":"2023","journal-title":"Future Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"115368","DOI":"10.1016\/j.ejca.2025.115368","article-title":"Conference on challenges in sarcoma (CCS) 2024: Expert opinions on non-evidence-based management aspects","volume":"220","author":"Hofer","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"102565","DOI":"10.1016\/j.esmoop.2024.102565","article-title":"140TiP Brightline-4: A phase III open-label, single-arm, multicentre study to assess the safety and efficacy of brigimadlin (BI 907828), an MDM2-p53 antagonist, in patients with treatment-na\u00efve or pretreated advanced dedifferentiated liposarcoma","volume":"9","author":"Schuetze","year":"2024","journal-title":"ESMO Open"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Liu, H., Wang, X., Wang, X., Qiu, F., and Zhou, B. (2025). Challenges and hope: Latest research trends in the clinical treatment and prognosis of liposarcoma. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1529755"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/ng.619","article-title":"Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy","volume":"42","author":"Barretina","year":"2010","journal-title":"Nat. Genet."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jamaoncol.2016.0264","article-title":"Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial","volume":"2","author":"Dickson","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"11004","DOI":"10.1200\/JCO.2019.37.15_suppl.11004","article-title":"Phase 2 study of the CDK4 inhibitor abemaciclib in dedifferentiated liposarcoma","volume":"37","author":"Dickson","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"TPS11587","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS11587","article-title":"A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma","volume":"41","author":"Dickson","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_49","unstructured":"ClinicalTrials.gov (2026, February 07). SARC041: Study of Abemaciclib Versus Placebo in Patients with Advanced Dedifferentiated Liposarcoma, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04967521."},{"key":"ref_50","unstructured":"ClinicalTrials.gov (2026, February 07). A Phase 2 Study of Palbociclib and Retifanlimab in Patients With Well-Differentiated or Dedifferentiated Liposarcoma, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04438824."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Traweek, R.S., Cope, B.M., Roland, C.L., Keung, E.Z., Nassif, E.F., and Erstad, D.J. (2022). Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1006959"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1200\/JCO.21.01829","article-title":"Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial","volume":"40","author":"Gounder","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.ejca.2020.10.032","article-title":"A phase 1b trial of selinexor, a first-in-class selective inhibitor of nuclear export (SINE), in combination with doxorubicin in patients with advanced soft tissue sarcomas (STS)","volume":"144","author":"Lewin","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1200\/JCO-24-01466","article-title":"Letetresgene Autoleucel in Advanced\/Metastatic Myxoid\/Round Cell Liposarcoma","volume":"43","author":"Druta","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1158\/1078-0432.CCR-25-0595","article-title":"FDA Approval Summary: Afamitresgene Autoleucel for Adults with HLA-Restricted, MAGE-A4-Positive Unresectable or Metastatic Synovial Sarcoma after Prior Chemotherapy","volume":"31","author":"Barnett","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1158\/1078-0432.CCR-23-2378","article-title":"Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma","volume":"30","author":"Gleason","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13045-017-0482-3","article-title":"Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas","volume":"10","author":"Chaire","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s12032-025-02651-2","article-title":"Selinexor in the treatment of liposarcoma: From preclinical evidence to clinical practice","volume":"42","author":"Remiszewski","year":"2025","journal-title":"Med. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"7521","DOI":"10.18632\/oncotarget.13485","article-title":"Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma","volume":"8","author":"Garg","year":"2017","journal-title":"Oncotarget"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Marretta, A.L., Di Lorenzo, G., Ribera, D., Cannella, L., von Arx, C., Bracigliano, A., Clemente, O., Tafuto, R., Pizzolorusso, A., and Tafuto, S. (2021). Selinexor and the Selective Inhibition of Nuclear Export: A New Perspective on the Treatment of Sarcomas and Other Solid and Non-Solid Tumors. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13091522"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1158\/1078-0432.CCR-16-2632","article-title":"Selinexor (KPT-330) Induces Tumor Suppression through Nuclear Sequestration of I\u03baB and Downregulation of Survivin","volume":"23","author":"Nair","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1309\/AJCPLYU89XHSNHQO","article-title":"MDM2 copy numbers in well-differentiated and dedifferentiated liposarcoma: Characterizing progression to high-grade tumors","volume":"141","author":"Ware","year":"2014","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1007\/s00432-022-04247-z","article-title":"The efficacy of selinexor (KPT-330), an XPO1 inhibitor, on non-hematologic cancers: A comprehensive review","volume":"149","author":"Landes","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1200\/JCO.2016.67.6346","article-title":"Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma","volume":"34","author":"Gounder","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/leu.2016.145","article-title":"KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells","volume":"31","author":"Etchin","year":"2017","journal-title":"Leukemia"},{"key":"ref_66","first-page":"1268","article-title":"NY-ESO-1 as a diagnostic and prognostic marker for myxoid liposarcoma","volume":"14","author":"Jo","year":"2022","journal-title":"Am. J. Transl. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1002\/ijc.34453","article-title":"A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma","volume":"152","author":"Ishihara","year":"2023","journal-title":"Int. J. Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e23535","DOI":"10.1200\/JCO.2023.41.16_suppl.e23535","article-title":"Epidemiology, survival, and treatment of liposarcoma subtypes: An analysis of the national cancer database","volume":"41","author":"Kennard","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_69","unstructured":"(2026, February 07). Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid\/Round Cell Liposarcoma (MRCLS). Press Release. Available online: https:\/\/www.adaptimmune.com."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"D\u2019Angelo, S.P., Furness, A.J.S., Thistlethwaite, F., Burgess, M.A., Riedel, R.F., Haanen, J., Noujaim, J., Chalmers, A.W., Pousa, A.L., and Chugh, R. (2024, January 13\u201316). Primary analysis of the pivotal IGNYTE-ESO trial of lete-cel in patients with synovial sarcoma or myxoid\/round cell liposarcoma. Proceedings of the 2024 CTOS Annual Meeting, San Diego, CA, USA. Abstract P84.","DOI":"10.1200\/JCO.2024.42.16_suppl.2500"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): A multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1158\/1078-0432.CCR-19-1824","article-title":"Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab","volume":"26","author":"Keung","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"11008","DOI":"10.1200\/JCO.2017.35.15_suppl.11008","article-title":"Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): Final results of SARC028 and biomarker analyses","volume":"35","author":"Burgess","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/s41591-022-01821-3","article-title":"Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: A phase 2 PEMBROSARC trial cohort","volume":"28","author":"Italiano","year":"2022","journal-title":"Nat. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e009472","DOI":"10.1136\/jitc-2024-009472","article-title":"A multicenter, randomized, non-comparative, phase II study of nivolumab \u00b1 ipilimumab for patients with metastatic sarcoma (Alliance A091401): Expansion cohorts and correlative analyses","volume":"12","author":"Seligson","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"11511","DOI":"10.1200\/JCO.2020.38.15_suppl.11511","article-title":"A multicenter phase II study of nivolumab +\/\u2212 ipilimumab for patients with metastatic sarcoma (Alliance A091401): Results of expansion cohorts","volume":"38","author":"Chen","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s43018-024-00726-z","article-title":"A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity\/truncal undifferentiated pleomorphic sarcoma","volume":"5","author":"Roland","year":"2024","journal-title":"Nat. Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/jso.28155","article-title":"Neoadjuvant Immunotherapy for Resectable Dedifferentiated Liposarcoma: A National Cohort Analysis","volume":"131","author":"Farooq","year":"2025","journal-title":"J. Surg. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(18)30006-8","article-title":"Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): Two open-label, non-comparative, randomised, phase 2 trials","volume":"19","author":"Mahoney","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e1655","DOI":"10.1634\/theoncologist.2020-0679","article-title":"A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced\/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study","volume":"25","author":"Riedel","year":"2020","journal-title":"Oncologist"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1158\/1078-0432.CCR-22-3351","article-title":"A Single-Arm Phase II Trial of Sitravatinib in Advanced Well-Differentiated\/Dedifferentiated Liposarcoma","volume":"29","author":"Ingham","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.18632\/oncotarget.6547","article-title":"Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma","volume":"7","author":"Patwardhan","year":"2016","journal-title":"Oncotarget"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.1158\/1078-0432.CCR-23-3983","article-title":"First-Line Anlotinib Treatment for Soft-Tissue Sarcoma in Chemotherapy-Ineligible Patients: An Open-Label, Single-Arm, Phase 2 Clinical Trial","volume":"30","author":"Li","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1158\/1078-0432.CCR-17-3766","article-title":"Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma","volume":"24","author":"Chi","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"102240","DOI":"10.1016\/j.eclinm.2023.102240","article-title":"Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): A multicentre, open-label, single-arm, phase 2 trial","volume":"64","author":"Xu","year":"2023","journal-title":"EClinicalMedicine"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13045-018-0664-7","article-title":"Anlotinib: A novel multi-targeting tyrosine kinase inhibitor in clinical development","volume":"11","author":"Shen","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.21873\/invivo.12997","article-title":"Chloroquine Combined With Rapamycin Arrests Tumor Growth in a Patient-derived Orthotopic Xenograft (PDOX) Mouse Model of Dedifferentiated Liposarcoma","volume":"36","author":"Masaki","year":"2022","journal-title":"In Vivo"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"317","DOI":"10.21873\/cgp.20384","article-title":"Targeting Autophagy With the Synergistic Combination of Chloroquine and Rapamycin as a Novel Effective Treatment for Well-differentiated Liposarcoma","volume":"20","author":"Masaki","year":"2023","journal-title":"Cancer Genom. Proteom."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1200\/JCO.2007.12.0345","article-title":"Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies","volume":"26","author":"Mita","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1200\/JCO.2012.45.5766","article-title":"Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy","volume":"31","author":"Demetri","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.ajpath.2013.01.002","article-title":"Novel dedifferentiated liposarcoma xenograft models reveal PTEN down-regulation as a malignant signature and response to PI3K pathway inhibition","volume":"182","author":"Smith","year":"2013","journal-title":"Am. J. Pathol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1634\/theoncologist.12-8-1007","article-title":"The biology behind mTOR inhibition in sarcoma","volume":"12","author":"Wan","year":"2007","journal-title":"Oncologist"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"5965","DOI":"10.18632\/oncotarget.2023","article-title":"Identification of a gene expression driven progression pathway in myxoid liposarcoma","volume":"5","author":"Negri","year":"2014","journal-title":"Oncotarget"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.1038\/onc.2016.157","article-title":"miR-135b, a key regulator of malignancy, is linked to poor prognosis in human myxoid liposarcoma","volume":"35","author":"Nezu","year":"2016","journal-title":"Oncogene"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.18632\/oncotarget.27144","article-title":"Inhibition of histone deacetylase 2 reduces MDM2 expression and reduces tumor growth in dedifferentiated liposarcoma","volume":"10","author":"Seligson","year":"2019","journal-title":"Oncotarget"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41389-018-0026-x","article-title":"Histone deacetylase inhibitor ITF2357 leads to apoptosis and enhances doxorubicin cytotoxicity in preclinical models of human sarcoma","volume":"7","author":"Desideri","year":"2018","journal-title":"Oncogenesis"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1158\/1078-0432.CCR-21-1291","article-title":"Co-Targeting of MDM2 and CDK4\/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study","volume":"28","author":"Bauer","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1136\/jcp.2009.070201","article-title":"Can MDM2 and CDK4 make the diagnosis of well differentiated\/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours","volume":"62","author":"Aleixo","year":"2009","journal-title":"J. Clin. Pathol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s12094-025-03989-9","article-title":"Prognostic Implications of MDM2 and CDK4 Co-amplification in Liposarcoma: Insights from FISH analysis for Translational Oncology","volume":"28","author":"James","year":"2026","journal-title":"Clin. Transl. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"19891","DOI":"10.18632\/oncotarget.24924","article-title":"Targeted next generation sequencing of well-differentiated\/dedifferentiated liposarcoma reveals novel gene amplifications and mutations","volume":"9","author":"Somaiah","year":"2018","journal-title":"Oncotarget"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1245\/s10434-023-13500-9","article-title":"A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients with High-Risk Retroperitoneal Sarcoma (STRASS2)","volume":"30","author":"Lambdin","year":"2023","journal-title":"Ann. Surg. Oncol."},{"key":"ref_102","unstructured":"ClinicalTrials.gov (2026, February 07). EORTC 1809 (STRASS2): A Randomized Phase III Study of Neoadjuvant Chemotherapy followed by Surgery versus Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05234606."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e71129","DOI":"10.1002\/cam4.71129","article-title":"Surgical Management of Retroperitoneal Liposarcoma: Opportunities for Multimodality Treatment, Including Systemic Therapy","volume":"14","author":"Sun","year":"2025","journal-title":"Cancer Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.suc.2016.06.006","article-title":"Systemic Therapy for Advanced Soft Tissue Sarcoma","volume":"96","author":"Sheng","year":"2016","journal-title":"Surg. Clin. North Am."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/S1470-2045(17)30334-0","article-title":"Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): An international, open-label, randomised, controlled, phase 3, multicentre trial","volume":"18","author":"Gronchi","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1200\/JCO.23.00908","article-title":"Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish Sarcoma Groups (PSG)","volume":"42","author":"Gronchi","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/S0140-6736(24)01812-9","article-title":"Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): An open-label, randomised clinical trial","volume":"404","author":"Mowery","year":"2024","journal-title":"Lancet"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1245\/s10434-020-09290-z","article-title":"Renal Function After Retroperitoneal Sarcoma Resection with Nephrectomy: A Matched Analysis of the United States Sarcoma Collaborative Database","volume":"28","author":"Stahl","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1002\/ijc.32216","article-title":"Genotyping of circulating cell-free DNA enables noninvasive tumor detection in myxoid liposarcomas","volume":"145","author":"Braig","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Braig, D., Runkel, A., Eisenhardt, A.E., Schmid, A., Zeller, J., Pauli, T., Lausch, U., Wehrle, J., Bronsert, P., and Jung, M. (2022). Individualized Mini-Panel Sequencing of ctDNA Allows Tumor Monitoring in Complex Karyotype Sarcomas. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231810215"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12943-022-01523-x","article-title":"Targeted next-generation sequencing of circulating free DNA enables non-invasive tumor detection in myxoid liposarcomas","volume":"21","author":"Eisenhardt","year":"2022","journal-title":"Mol. Cancer"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e70704","DOI":"10.1002\/cam4.70704","article-title":"Improved Quantification of Circulating Tumor DNA in Translocation-Associated Myxoid Liposarcoma by Simultaneous Detection of Breakpoints and Single Nucleotide Variants","volume":"14","author":"Schmid","year":"2025","journal-title":"Cancer Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"104345","DOI":"10.1016\/j.critrevonc.2024.104345","article-title":"Patient-reported outcomes in randomized clinical trials of systemic therapy for advanced soft tissue sarcomas in adults: A systematic review","volume":"197","author":"Roets","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e23552","DOI":"10.1200\/JCO.2024.42.16_suppl.e23552","article-title":"Quality of life outcomes in patients with resectable dedifferentiated liposarcoma treated with neoadjuvant immunotherapy","volume":"42","author":"Malik","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1080\/14737140.2018.1524298","article-title":"Preserving quality of life as a key treatment goal in advanced soft tissue sarcomas","volume":"18","author":"Jones","year":"2018","journal-title":"Expert Rev. Anticancer. Ther."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/11\/1694\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T16:13:59Z","timestamp":1779466439000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/11\/1694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":115,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["cancers18111694"],"URL":"https:\/\/doi.org\/10.3390\/cancers18111694","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]}}}